In one paragraphReview in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Joost M MeijerDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, Netherlands. j.m.meijer@umcg.nl.ORCID 0000-0001-7654-3528 Elise J LeemanDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, Netherlands.ORCID 0009-0007-0770-136X Dominika GrabikDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, Netherlands.
Lisette M PrensDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, Netherlands.ORCID 0000-0002-3751-684X Klasiena BouwmanDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, Netherlands.ORCID 0000-0002-4756-1433 Jelmer R PrinsDepartment of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.ORCID 0000-0002-3984-2163 Sanne J GordijnDepartment of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.ORCID 0000-0003-3915-8609 Mirthe H SchootsDepartment of Pathology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.ORCID 0000-0003-2168-2517 Maria C BollingDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, Netherlands.ORCID 0000-0003-2086-9363 Gilles F H DiercksDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, Netherlands; Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.ORCID 0000-0001-8053-216X Jeroen BremerDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, Netherlands.ORCID 0000-0002-7550-6386 Barbara HorváthDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, Netherlands.ORCID 0000-0001-8559-3674 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Treatment of pemphigoid gestationis (PG) mainly consists of systemic and potent topical corticosteroids. This retrospective case series describes patients with severe PG treated with dupilumab, including serological follow-up, and reviews all published cases. PG was confirmed by direct immunofluorescence (linear C3 and/or IgG deposition along the basement membrane zone) and serology (IgG epidermal staining on salt-split skin or anti-BP180 NC16A IgG ELISA). Pruritus, quality of life and anti-BP180 NC16A IgG and anti-BP180 NC16A IgE were monitored longitudinally. In 5 pregnant women, dupilumab was initiated with a 600 mg loading dose followed by 300 mg biweekly. Baseline pruritus was severe (NRS 8-10), with high DLQI scores (18-30). Blistering ceased within 1 week in 2 patients and within 4 weeks in 1. Two patients required weekly dosing for disease control. Systemic corticosteroids were discontinued in 3 patients and tapered to ≤10 mg/day in 2 before delivery. In one case, anti-BP180 IgG paralleled clinical improvement. Anti-BP180 IgE remained negative. All patients delivered healthy infants. In 10 reported cases, pruritus improved rapidly and systemic corticosteroids were tapered. These findings suggest dupilumab may be a promising corticosteroid-sparing option for PG, with rapid clinical response and a favourable safety profile, despite off-label use in pregnancy.
Indexed as
Antibodies, Monoclonal, HumanizedPemphigoid GestationisAdultCollagen Type XVIIFemaleHumansNon-Fibrillar CollagensPregnancyPruritusRetrospective StudiesTime FactorsTreatment OutcomeAntibodies, Monoclonal, HumanizedCollagen Type XVIIdupilumabNon-Fibrillar Collagens
Identifiers
PMID42516098
PMCPMC13408254
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390